A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder

Laura A. Potter, Danielle A. Scholze, Hazel Maridith B. Biag, Andrea Schneider, Yanjun Chen, Danh V. Nguyen, Akash Rajaratnam, Susan M. Rivera, Patrick S. Dwyer, Flora Tassone, Reem R. Al Olaby, Nimrah S. Choudhary, Maria J. Salcedo-Arellano, Randi J. Hagerman

Research output: Contribution to journalArticle

Abstract

Objective: Selective serotonin reuptake inhibitors like sertraline have been shown in observational studies and anecdotal reports to improve language development in young children with fragile X syndrome (FXS). A previous controlled trial of sertraline in young children with FXS found significant improvement in expressive language development as measured by the Mullen Scales of Early Learning (MSEL) among those with comorbid autism spectrum disorder (ASD) in post hoc analysis, prompting the authors to probe whether sertraline is also indicated in nonsyndromic ASD. Methods: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 58 children with ASD aged 24 to 72 months. Results: 179 subjects were screened for eligibility, and 58 were randomized to sertraline (32) or placebo (26). Eight subjects from the sertraline arm and five from the placebo arm discontinued. Intent-to-treat analysis showed no significant difference from placebo on the primary outcomes (MSEL expressive language raw score and age equivalent combined score) or secondary outcomes. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events possibly related to study treatment occurred. Conclusion: This randomized controlled trial of sertraline treatment showed no benefit with respect to primary or secondary outcome measures. For the 6-month period, treatment in young children with ASD appears safe, although the long-term side effects of low-dose sertraline in early childhood are unknown. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02385799.

Original languageEnglish (US)
Article number810
JournalFrontiers in Psychiatry
Volume10
DOIs
StatePublished - Nov 6 2019

Fingerprint

Sertraline
Randomized Controlled Trials
Placebos
Fragile X Syndrome
Language Development
Autism Spectrum Disorder
Learning
Serotonin Uptake Inhibitors
Therapeutics
Observational Studies
Language
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • autism spectrum disorder
  • controlled trial
  • nonsyndromic autism spectrum disorder
  • sertraline
  • targeted treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder. / Potter, Laura A.; Scholze, Danielle A.; Biag, Hazel Maridith B.; Schneider, Andrea; Chen, Yanjun; Nguyen, Danh V.; Rajaratnam, Akash; Rivera, Susan M.; Dwyer, Patrick S.; Tassone, Flora; Al Olaby, Reem R.; Choudhary, Nimrah S.; Salcedo-Arellano, Maria J.; Hagerman, Randi J.

In: Frontiers in Psychiatry, Vol. 10, 810, 06.11.2019.

Research output: Contribution to journalArticle

Potter, LA, Scholze, DA, Biag, HMB, Schneider, A, Chen, Y, Nguyen, DV, Rajaratnam, A, Rivera, SM, Dwyer, PS, Tassone, F, Al Olaby, RR, Choudhary, NS, Salcedo-Arellano, MJ & Hagerman, RJ 2019, 'A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder', Frontiers in Psychiatry, vol. 10, 810. https://doi.org/10.3389/fpsyt.2019.00810
Potter, Laura A. ; Scholze, Danielle A. ; Biag, Hazel Maridith B. ; Schneider, Andrea ; Chen, Yanjun ; Nguyen, Danh V. ; Rajaratnam, Akash ; Rivera, Susan M. ; Dwyer, Patrick S. ; Tassone, Flora ; Al Olaby, Reem R. ; Choudhary, Nimrah S. ; Salcedo-Arellano, Maria J. ; Hagerman, Randi J. / A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder. In: Frontiers in Psychiatry. 2019 ; Vol. 10.
@article{0022b0977ed342afb080349bfbe902b7,
title = "A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder",
abstract = "Objective: Selective serotonin reuptake inhibitors like sertraline have been shown in observational studies and anecdotal reports to improve language development in young children with fragile X syndrome (FXS). A previous controlled trial of sertraline in young children with FXS found significant improvement in expressive language development as measured by the Mullen Scales of Early Learning (MSEL) among those with comorbid autism spectrum disorder (ASD) in post hoc analysis, prompting the authors to probe whether sertraline is also indicated in nonsyndromic ASD. Methods: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 58 children with ASD aged 24 to 72 months. Results: 179 subjects were screened for eligibility, and 58 were randomized to sertraline (32) or placebo (26). Eight subjects from the sertraline arm and five from the placebo arm discontinued. Intent-to-treat analysis showed no significant difference from placebo on the primary outcomes (MSEL expressive language raw score and age equivalent combined score) or secondary outcomes. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events possibly related to study treatment occurred. Conclusion: This randomized controlled trial of sertraline treatment showed no benefit with respect to primary or secondary outcome measures. For the 6-month period, treatment in young children with ASD appears safe, although the long-term side effects of low-dose sertraline in early childhood are unknown. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02385799.",
keywords = "autism spectrum disorder, controlled trial, nonsyndromic autism spectrum disorder, sertraline, targeted treatment",
author = "Potter, {Laura A.} and Scholze, {Danielle A.} and Biag, {Hazel Maridith B.} and Andrea Schneider and Yanjun Chen and Nguyen, {Danh V.} and Akash Rajaratnam and Rivera, {Susan M.} and Dwyer, {Patrick S.} and Flora Tassone and {Al Olaby}, {Reem R.} and Choudhary, {Nimrah S.} and Salcedo-Arellano, {Maria J.} and Hagerman, {Randi J.}",
year = "2019",
month = "11",
day = "6",
doi = "10.3389/fpsyt.2019.00810",
language = "English (US)",
volume = "10",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder

AU - Potter, Laura A.

AU - Scholze, Danielle A.

AU - Biag, Hazel Maridith B.

AU - Schneider, Andrea

AU - Chen, Yanjun

AU - Nguyen, Danh V.

AU - Rajaratnam, Akash

AU - Rivera, Susan M.

AU - Dwyer, Patrick S.

AU - Tassone, Flora

AU - Al Olaby, Reem R.

AU - Choudhary, Nimrah S.

AU - Salcedo-Arellano, Maria J.

AU - Hagerman, Randi J.

PY - 2019/11/6

Y1 - 2019/11/6

N2 - Objective: Selective serotonin reuptake inhibitors like sertraline have been shown in observational studies and anecdotal reports to improve language development in young children with fragile X syndrome (FXS). A previous controlled trial of sertraline in young children with FXS found significant improvement in expressive language development as measured by the Mullen Scales of Early Learning (MSEL) among those with comorbid autism spectrum disorder (ASD) in post hoc analysis, prompting the authors to probe whether sertraline is also indicated in nonsyndromic ASD. Methods: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 58 children with ASD aged 24 to 72 months. Results: 179 subjects were screened for eligibility, and 58 were randomized to sertraline (32) or placebo (26). Eight subjects from the sertraline arm and five from the placebo arm discontinued. Intent-to-treat analysis showed no significant difference from placebo on the primary outcomes (MSEL expressive language raw score and age equivalent combined score) or secondary outcomes. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events possibly related to study treatment occurred. Conclusion: This randomized controlled trial of sertraline treatment showed no benefit with respect to primary or secondary outcome measures. For the 6-month period, treatment in young children with ASD appears safe, although the long-term side effects of low-dose sertraline in early childhood are unknown. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02385799.

AB - Objective: Selective serotonin reuptake inhibitors like sertraline have been shown in observational studies and anecdotal reports to improve language development in young children with fragile X syndrome (FXS). A previous controlled trial of sertraline in young children with FXS found significant improvement in expressive language development as measured by the Mullen Scales of Early Learning (MSEL) among those with comorbid autism spectrum disorder (ASD) in post hoc analysis, prompting the authors to probe whether sertraline is also indicated in nonsyndromic ASD. Methods: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 58 children with ASD aged 24 to 72 months. Results: 179 subjects were screened for eligibility, and 58 were randomized to sertraline (32) or placebo (26). Eight subjects from the sertraline arm and five from the placebo arm discontinued. Intent-to-treat analysis showed no significant difference from placebo on the primary outcomes (MSEL expressive language raw score and age equivalent combined score) or secondary outcomes. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events possibly related to study treatment occurred. Conclusion: This randomized controlled trial of sertraline treatment showed no benefit with respect to primary or secondary outcome measures. For the 6-month period, treatment in young children with ASD appears safe, although the long-term side effects of low-dose sertraline in early childhood are unknown. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02385799.

KW - autism spectrum disorder

KW - controlled trial

KW - nonsyndromic autism spectrum disorder

KW - sertraline

KW - targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=85075545177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075545177&partnerID=8YFLogxK

U2 - 10.3389/fpsyt.2019.00810

DO - 10.3389/fpsyt.2019.00810

M3 - Article

AN - SCOPUS:85075545177

VL - 10

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

SN - 1664-0640

M1 - 810

ER -